title: [New therapy schemes for acute, subacute and chronic variants of extrinsic allergic alveolitis].
abstract: In order to improve treatment of patients with exogenous allergic alveolitis morphologically different variants of the disease, i.e. acute, subacute and chronic were identified and confirmed. For each variant of exogenous allergic alveolitis new therapy schemes were proposed. The study included 74 patients who were divided into 5 groups. In the first group with acute exogenous allergic alveolitis inhalation glycocorticosteroids in high doses in combination with plasmapheresis were prescribed, in the second group standard therapy with systemic glycocorticosteroids was prescribed. The third and the fourth group consisted of patients with subacute exogenous allergic alveolitis. The protracted ambroxol inhalation using nebulizers and the reduced dose of systemic glycocorticosteroids were used in the third group; and the standard dose of systemic glycocorticosteroids was used in the fourth. The fifth group consisted of patients with chronic exogenous allergic alveolitis, who received the standard dose of glycocorticosteroids and cytostatic drugs. After one month of therapy, it was ascertained that the use of high doses of inhalation glycocorticosteroids in combination with plasmapheresis in patients with acute exogenous allergic alveolitis led to significant improvements in clinical and CT presentation, physical activity tolerance, as well as the use of systemic glycocorticosteroids. The use of ambroxol inhalation in patients with subacute exogenous allergic alveolitis led to a significant improvement in clinical symptomatology, functional parameters and CT presentation, thus enabling to reduce the dose of glycocorticosteroids used and to avoid unwanted side effects.
authors: N N
authors: NN
authors: Makar'iants
authors: E I
authors: EI
authors: Shmelev
mesh_terms: D000328:Adult; D000542:Alveolitis, Extrinsic Allergic / Q000188:drug therapy*; D000551:Ambroxol / Q000008:administration & dosage; D004333:Drug Administration Routes; D005100:Expectorants / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010956:Plasmapheresis / Q000379:methods*; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005100:Expectorants; D005938:Glucocorticoids; D011663:Pulmonary Surfactants; D000551:Ambroxol